Purpose In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam
(OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently …

Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Background and objective Major changes in cytochrome P450 (CYP) 3A activity may be
expected in the first few months of life with, later, relatively limited changes. In this analysis …

Purpose We report the case of a male neonate with a respiratory disorder who developed
adverse cardiorespiratory symptoms after the continuous infusion of midazolam. Methods To …

A simple, selective high‐performance liquid chromatographic method with ultraviolet
detection at 220nm is described for quantitation of midazolam and its primary metabolite 1 …

Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …